SFPM(SZ:002737) Xin Lang Cai Jing·2026-02-26 01:36Core Viewpoint - On February 25, 2025, Kewah Pharmaceutical's stock increased by 0.43%, with a trading volume of 30.14 million yuan. The company experienced a net financing outflow of 680,200 yuan on that day, indicating a low financing balance relative to its market value [1]. Financing Summary - Kewah Pharmaceutical had a financing buy-in of 3.40 million yuan on February 25, with a current financing balance of 128 million yuan, accounting for 1.56% of its circulating market value. This financing balance is below the 10th percentile level over the past year, indicating a low position [1]. - In terms of securities lending, the company repaid 2,500 shares and sold 500 shares on February 25, with a selling amount of 7,045 yuan. The current securities lending balance is 2.18 million yuan, which exceeds the 90th percentile level over the past year, indicating a high position [1]. Financial Performance - As of December 31, 2025, Kewah Pharmaceutical reported a revenue of 1.684 billion yuan for the first nine months, a year-on-year decrease of 43.24%. The net profit attributable to shareholders was -33.54 million yuan, a year-on-year decrease of 105.72% [2]. - Cumulatively, since its A-share listing, Kewah Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, Kewah Pharmaceutical had 48,000 shareholders, a decrease of 2.04% from the previous period. The average circulating shares per person increased by 2.08% to 12,166 shares [2]. - Among the top ten circulating shareholders, E Fund CSI Dividend ETF (515180) is the fifth largest, holding 3.4008 million shares, an increase of 239,600 shares from the previous period. Hong Kong Central Clearing Limited is the seventh largest, holding 2.8412 million shares, a decrease of 128,700 shares [3].